Document 0280
 DOCN  M94A0280
 TI    Clinical and immunologic evaluation of HIV-infected patients treated
       with dinitrochlorobenzene.
 DT    9412
 AU    Stricker RB; Elswood BF; Goldberg B; Dumlao C; Van Elk J; Henry J;
       Winger EE; Epstein WL; HemaCare Corporation, San Francisco, CA 94108.
 SO    J Am Acad Dermatol. 1994 Sep;31(3 Pt 1):462-6. Unique Identifier :
       AIDSLINE MED/94358210
 AB    BACKGROUND: Promotion of cell-mediated immunity appears to be an
       important goal in the control of HIV infection. Topical
       dinitrochlorobenzene (DNCB) stimulates systemic cell-mediated immunity
       via the induction of cutaneous delayed-type hypersensitivity. OBJECTIVE:
       Our goal was to evaluate the clinical and immunologic effects of chronic
       DNCB application in a group of 24 HIV-infected patients. METHODS: We
       observed the patients for a mean of 28 months (range, 14 to 44 months).
       Of the 24 patients, 13 continued weekly DNCB application throughout the
       study (the compliant group), and 11 discontinued DNCB use after a mean
       of 10.9 months (the noncompliant group). RESULTS: Two of the 13
       compliant patients progressed to AIDS; none of these patients died. In
       contrast, AIDS developed in 5 of the 11 noncompliant patients and four
       of these patients died. Analysis of lymphocyte subsets revealed
       significant increases in natural killer cells and activated/cytotoxic
       CD8 T-cell subsets in the compliant group. In contrast, these cellular
       immune-related lymphocyte subsets decreased in the noncompliant
       subjects. Although CD4 T-cell levels decreased in both groups, there was
       a significantly greater drop in the noncompliant patients. CD8+CD38+ T
       cells increased significantly in both groups. CONCLUSION: Chronic DNCB
       application appears to have a beneficial clinical and immunomodulatory
       effect in HIV-infected patients.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY  Antigens, CD/ANALYSIS
       CD4-CD8 Ratio  Dinitrochlorobenzene/*THERAPEUTIC USE  Flow Cytometry
       Human  HIV Infections/DRUG THERAPY/*IMMUNOLOGY  Immunity, Cellular
       Lymphocyte Subsets  Male  Patient Compliance  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).